The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial

BACKGROUND: Our phase III clinical trial of pirfenidone for patients with idiopathic pulmonary fibrosis (IPF) revealed the efficacy in reducing the decline of vital capacity (VC) and increasing the progression-free survival (PFS) time by pirfenidone. Recently, marginal decline in forced VC (FVC) has...

Descripción completa

Detalles Bibliográficos
Autores principales: Taniguchi, Hiroyuki, Kondoh, Yasuhiro, Ebina, Masahito, Azuma, Arata, Ogura, Takashi, Taguchi, Yoshio, Suga, Moritaka, Takahashi, Hiroki, Nakata, Koichiro, Sato, Atsuhiko, Sugiyama, Yukihiko, Kudoh, Shoji, Nukiwa, Toshihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3160381/
https://www.ncbi.nlm.nih.gov/pubmed/21756364
http://dx.doi.org/10.1186/1465-9921-12-93

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3160381/
https://www.ncbi.nlm.nih.gov/pubmed/21756364
http://dx.doi.org/10.1186/1465-9921-12-93

Ejemplares similares